Phospho-ERBB3 (Y1197) Antibody

What distinguishes ERBB3 from other ERBB family members?

ERBB3 is structurally and functionally distinct from other ERBB family members (EGFR, ERBB2, ERBB4). While all ERBB receptors share high sequence homology in their tyrosine kinase domains (59-81% identity), ERBB3 has been traditionally characterized as a pseudokinase with limited catalytic activity. It shows more divergence in its ectodomain and C-terminal tail regions (only 12-30% sequence identity in the C-terminal tail) compared to other family members. These differences are reflected in knockout mouse models, where ERBB3-/- mice die at embryonic day 13.5 with distinct cardiac and neurological defects compared to those seen in ERBB2 or ERBB4 knockout mice .

What is the significance of the Y1197 phosphorylation site on ERBB3?

The Y1197 phosphorylation site is located in the C-terminal region of ERBB3 and represents one of the key regulatory sites for ERBB3 signaling. When phosphorylated, this site serves as a docking platform for downstream signaling molecules. The region around Y1197 (amino acids 1163-1212) has been specifically targeted for generating antibodies that can detect the active, phosphorylated state of ERBB3 . This phosphorylation site is critical for mediating ERBB3's role in various cellular processes including proliferation, survival, and differentiation, particularly in cancer contexts.

How does ERBB3 compensate for its diminished kinase activity?

Despite being considered a pseudokinase, ERBB3 functions by forming heterodimers with other ERBB family members, particularly ERBB2/HER2. In these heterodimeric complexes, ERBB3 can be trans-phosphorylated by its partner kinase. Recent research has challenged the complete "kinase-dead" perception, suggesting ERBB3 may retain some residual kinase activity. Additionally, ERBB3 contains multiple tyrosine phosphorylation sites in its C-terminal tail that, when phosphorylated, can potently activate downstream signaling pathways, especially the PI3K/AKT pathway . This allows ERBB3 to function as a signaling entity despite its limited intrinsic kinase activity.

What experimental techniques are optimal for detecting Phospho-ERBB3 (Y1197)?

The detection of Phospho-ERBB3 (Y1197) can be accomplished through several complementary techniques:

• Western Blotting (WB): The Anti-Phospho-ERBB3 (Y1197) antibody has been validated for WB applications at dilutions of 1:500-1:2000 . This technique allows for semi-quantitative analysis of phosphorylated ERBB3 levels in cell or tissue lysates.

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative assessment of Phospho-ERBB3 (Y1197), ELISA can be employed with the antibody at dilutions around 1:40000 .

• Mass Spectrometry: For comprehensive and unbiased phosphoproteomic analysis, techniques like those employed in the ERBB3/ERBB4 signaling study can identify thousands of phosphorylation sites, including those on ERBB3 .

• Immunofluorescence: This technique allows visualization of the spatial distribution of Phospho-ERBB3 within cells, as demonstrated in studies of ERBB3 expression in different TNBC subtypes .

How can researchers optimize antibody-based detection of Phospho-ERBB3 (Y1197)?

For optimal detection of Phospho-ERBB3 (Y1197) using antibody-based methods, researchers should consider:

• Sample Preparation: Preservation of phosphorylation states requires quick sample processing and inclusion of phosphatase inhibitors in lysis buffers.

• Antibody Validation: Confirm specificity using positive controls (cell lines known to express phosphorylated ERBB3) and negative controls (samples treated with phosphatases or ERBB3 inhibitors).

• Signal Enhancement: For low-abundance targets, consider using amplification systems such as biotin-streptavidin.

• Appropriate Blocking: Use 0.5% BSA (as found in the antibody formulation) for blocking to reduce background .

• Storage Conditions: Store the antibody at -20°C for long-term or at 4°C for up to one month to maintain activity. Avoid repeated freeze-thaw cycles as indicated in the product information .

What controls should be included when working with Phospho-ERBB3 (Y1197) antibodies?

To ensure reliable results with Phospho-ERBB3 (Y1197) antibodies, researchers should include:

• Positive Controls: Cell lines with known ERBB3 expression and activation, such as BT-20, HCC-70, or MDA-MB-468 (Basal-type TNBC cell lines) which display high HER3 expression .

• Negative Controls:

  • Untreated samples without ERBB3 activation

  • Samples treated with lambda phosphatase to remove phosphorylation

  • Cell lines with low ERBB3 expression, such as MDA-MB-231 or BT-549 (Claudin-type TNBC)

• Stimulation Controls: Samples treated with neuregulin-1 (NRG1), a known ligand that induces ERBB3 phosphorylation .

• Blocking Peptide Control: Using the synthesized peptide derived from the region around Y1197 to confirm antibody specificity .

How does ERBB3 expression and phosphorylation differ across cancer subtypes?

ERBB3 expression and phosphorylation patterns show distinct profiles across cancer subtypes, particularly in breast cancer:

• Triple-Negative Breast Cancer (TNBC) Subtypes:

  • Basal Type (BT-20, HCC-70, MDA-MB-468): Display predominantly high HER3 expression

  • Claudin Type (MDA-MB-231, BT-549): Show higher expression of NRG1 (the ligand) but lower HER3 receptor expression

This differential expression has functional consequences, as Basal-type TNBCs appear to rely more on EGFR-HER3-AKT pathway signaling compared to Claudin-type TNBCs .

• Mutation Status: ERBB3 mutations are frequently encountered in various cancer types, and these mutations can affect phosphorylation patterns, including at Y1197. Some mutations can lead to constitutive activation even in the absence of ligand binding .

• Co-expression Patterns: The expression and phosphorylation of ERBB3 should be evaluated in the context of other ERBB family members, particularly ERBB2/HER2, as their co-expression significantly impacts signaling outcomes .

How can Phospho-ERBB3 (Y1197) be used as a biomarker for therapeutic response?

Phospho-ERBB3 (Y1197) has potential as a biomarker for therapeutic response in several contexts:

• Prediction of Drug Sensitivity: Activating ERBB3 variants show sensitivity to ERBB2-targeting therapeutics, suggesting Phospho-ERBB3 (Y1197) status could predict response to such treatments .

• Resistance Mechanisms: EGFR and HER3 upregulation and activation have been implicated in resistance to small molecule inhibitors. Monitoring Phospho-ERBB3 (Y1197) levels before and during treatment could help identify emerging resistance .

• Treatment Selection: In TNBC, HER3 expression may identify patients who would respond to targeted inhibition of the EGFR/HER/AKT pathway versus those who would benefit least from such approaches .

• Combination Therapy Guidance: The phosphorylation status of ERBB3 can inform the potential efficacy of combination therapies. For example, dual inhibition with EGFR inhibitors and AKT/PI3K inhibitors showed enhanced efficacy in Basal TNBC cell lines with high HER3 expression but not in Claudin-type cell lines .

What is the relationship between ERBB3 phosphorylation and tumor progression?

The relationship between ERBB3 phosphorylation and tumor progression is multifaceted:

• Proliferation and Survival: Phosphorylated ERBB3 activates downstream signaling pathways, particularly PI3K/AKT, promoting cell proliferation and survival. In Ba/F3 cells, ERBB3 co-expression significantly enhanced cell proliferation upon NRG1 treatment .

• Metastatic Potential: Phosphorylated ERBB3 has been linked to cytoskeletal functions, which may contribute to increased cell motility and metastatic potential. Phosphoproteomics analysis revealed ERBB3/ERBB4 signaling links to cytoskeletal functions .

• Drug Resistance: Phosphorylation of ERBB3 can mediate resistance to targeted therapies, particularly those targeting other ERBB family members. This occurs through maintenance of downstream pathway activation despite inhibition of the primary target .

• Tumor Microenvironment Interactions: NRG1 in the tumor microenvironment can induce ERBB3 phosphorylation, providing a mechanism for microenvironment-mediated modulation of tumor behavior .

How does ERBB3 trans-activate other receptor tyrosine kinases?

ERBB3 trans-activation of other receptor tyrosine kinases involves several mechanisms:

• Heterodimer Formation: As a pseudokinase, ERBB3 primarily signals through formation of heterodimers with other ERBB family members, particularly ERBB2/HER2. In these heterodimers, ERBB3 can allosterically activate its partner kinase .

• Mutation-Induced Activation: Certain ERBB3 variants can promote cellular transformation specifically when forming heterodimeric complexes with ERBB2. For example, the iSCREAM approach identified ERBB3 variants that could transactivate ERBB2 V956R in Ba/F3 cells, promoting IL-3-independent growth .

• Ligand-Dependent Activation: Neuregulin-1 (NRG1) binding to ERBB3 induces conformational changes that promote heterodimer formation and trans-activation. This was demonstrated in quantitative phosphoproteomics studies showing that NRG1 treatment of ERBB3/ERBB4-expressing cells led to regulation of 492 phosphorylation sites .

• Signaling Amplification: ERBB3 contains multiple tyrosine phosphorylation sites in its C-terminal tail that, when phosphorylated, can recruit various signaling molecules, amplifying downstream pathway activation beyond what would be achieved by its heterodimer partner alone .

What are the differential downstream effects of various ERBB3 phosphorylation sites?

The multiple phosphorylation sites on ERBB3 have distinct roles in signaling:

• Y1197 Phosphorylation: This specific site is a key regulatory phosphorylation mark that mediates downstream signaling. While the search results don't detail the specific downstream effectors unique to Y1197, antibodies targeting this site are valuable for monitoring ERBB3 activation .

• PI3K/AKT Pathway Activation: Certain phosphorylation sites on ERBB3 directly bind the p85 regulatory subunit of PI3K, potently activating the PI3K/AKT pathway. This makes ERBB3 a major activator of this pathway among ERBB receptors .

• MAPK Pathway Regulation: Phosphoproteomics analysis of ERBB3/ERBB4 signaling revealed regulation of the MAPK pathway, indicating certain phosphorylation sites contribute to this signaling cascade .

• Site-Specific Signaling Networks: Comprehensive phosphoproteomics identified 9,686 phosphorylation sites, with 492 significantly changed in NRG1-treated ERBB3/ERBB4 cells. This reveals the complexity of the signaling networks initiated by ERBB3 phosphorylation .

• Cytoskeletal and Nuclear Regulation: Bioinformatics analysis of phosphoproteomics data indicated that ERBB3 phosphorylation has signaling links to cytoskeletal functions and nuclear biology, suggesting roles beyond classical RTK signaling pathways .

How does the pseudokinase nature of ERBB3 influence its signaling properties compared to active kinases?

The pseudokinase nature of ERBB3 creates unique signaling properties:

• Heterodimer Dependency: Unlike active kinases that can signal as homodimers, ERBB3 depends on heterodimer formation for signaling. This was demonstrated in Ba/F3 cell experiments where ERBB3 variants could not promote cell growth when expressed alone but required co-expression with ERBB2 .

• Signaling Amplification: Despite lacking strong kinase activity, ERBB3 can amplify signaling networks. In ERBB3/ERBB4 expressing cells, ERBB3 didn't trigger defined signaling pathways but broadly enhanced phosphoproteome regulation compared to cells expressing ERBB4 alone .

• Resistance to Kinase Inhibitors: The pseudokinase domain of ERBB3 may be less susceptible to ATP-competitive kinase inhibitors, making ERBB3-dependent signaling a potential mechanism of resistance to such inhibitors .

• Unique Structural Features: The pseudokinase domain has structural differences from active kinases that influence its interaction with other proteins and potential drug binding. The high degree of sequence conservation in ERBB tyrosine kinase domains (59-81%) means many small molecule inhibitors cross-react with multiple ERBB receptors, despite ERBB3's pseudokinase nature .

How can researchers address non-specific binding when using Phospho-ERBB3 (Y1197) antibodies?

To address non-specific binding issues with Phospho-ERBB3 (Y1197) antibodies:

• Optimized Blocking: Use appropriate blocking agents such as 0.5% BSA as indicated in the antibody formulation .

• Antibody Titration: Perform careful titration experiments to determine the optimal antibody concentration. For western blotting, the recommended dilution range is 1:500-1:2000, while for ELISA it's approximately 1:40000 .

• Validation with Blocking Peptide: Use the synthesized peptide derived from the region around the Y1197 phosphorylation site (amino acids 1163-1212) as a competitive inhibitor to confirm signal specificity .

• Phosphatase Controls: Treat duplicate samples with lambda phosphatase to confirm that the signal detected is specifically from phosphorylated ERBB3.

• Cross-Reactivity Testing: Validate specificity using cell lines with known ERBB3 expression levels, such as the contrasting Basal and Claudin type TNBC cell lines .

How should researchers interpret discrepancies between total ERBB3 and Phospho-ERBB3 (Y1197) data?

When faced with discrepancies between total ERBB3 and Phospho-ERBB3 (Y1197) data:

• Activation Status Assessment: Differences may reflect genuine biological variation in ERBB3 activation state rather than technical issues. For example, Basal-type TNBC cells express high levels of HER3 protein but may show variable phosphorylation depending on ligand availability .

• Temporal Dynamics: Consider that phosphorylation is dynamic and responsive to stimuli, while total protein levels change more slowly. Time-course experiments following NRG1 stimulation can help characterize this relationship .

• Localization Differences: Phosphorylated ERBB3 may localize differently within cells compared to total ERBB3, affecting detection in subcellular fractionation or immunofluorescence studies.

• Technical Considerations:

  • Antibody affinities differ between phospho-specific and total protein antibodies

  • Phospho-epitopes may be more sensitive to sample preparation methods

  • Storage conditions (temperature, freeze-thaw cycles) may differentially affect phospho-epitopes

• Phosphatase Activity: Endogenous phosphatase activity during sample preparation can reduce phospho-signals without affecting total protein detection.

What are the critical parameters for quantitative analysis of Phospho-ERBB3 (Y1197) in complex biological samples?

For accurate quantitative analysis of Phospho-ERBB3 (Y1197) in complex samples:

• Standardized Sample Processing:

  • Rapid sample collection and processing to preserve phosphorylation status

  • Consistent use of phosphatase and protease inhibitors

  • Standardized protein extraction and quantification methods

• Appropriate Normalization Strategies:

  • Normalize to total ERBB3 levels to account for expression differences

  • Include housekeeping protein controls

  • Consider normalization to cell number or tissue weight for cross-sample comparisons

• Quantification Methods:

  • For western blotting: Use linear range of detection and digital imaging

  • For ELISA: Include standard curves with recombinant phosphorylated proteins

  • For MS approaches: Consider isotope labeling (like mTRAQ) as used in ERBB3/ERBB4 signaling studies

• Biological Contextualization:

  • Account for heterogeneity in complex samples (e.g., tumor tissues)

  • Consider the impact of the tumor microenvironment, particularly NRG1 levels

  • Evaluate ERBB3 phosphorylation in the context of other ERBB family members' expression and activation